Data analyses show that people with Type 2 diabetes using GLP-1 medicines saw a significant improvement in their HbA1C after adding FreeStyle Libre technology to their regimen Better HbA1c results ...

The FreeStyle Libre 3 system is the most accurate 14-day continuous glucose monitor1, with readings sent directly to a smartphone every minute.2 Designed for access and affordability, the FreeStyle ...

Credit: Abbott. The FreeStyle Libre 3 reader is a standalone, small handheld device that displays real-time glucose readings. The Food and Drug Administration (FDA) has cleared a standalone reader to ...

First and only continuous glucose monitoring system to be nationally reimbursed in France for people who use once-daily (basal) insulin 1 Expanded reimbursement facilitates wider access to continuous ...

Data from Abbott’s REFLECT study show for the first time that the use of its continuous glucose monitoring technology, Freestyle Libre, can help lessen the severity of cardiovascular complications in ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Tidepool, a software company committed to innovations in diabetes management, is thrilled to announce a new data integration with continuous glucose monitoring (CGM ...

Abbott Laboratories says its not afraid that GLP-1 drugs will hurt the continuous glucose monitor (CGM) market. Abbott on Thursday released an analysis of patients' use of increasingly popular drugs ...

As it embarks on a widespread effort to remind users of the proper care and keeping of the hand-held readers used with its FreeStyle Libre continuous glucose monitors, Abbott is further expanding the ...

Tidepool collaborates with Abbott for seamless data integration with its FreeStyle Libre portfolio in the U.S., expanding patient choice and streamlining diabetes care workflows. PALO ALTO, ...

ABBOTT PARK, Ill., May 31, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle Libre 3 system for use by people ...

"Our goal is to get our FreeStyle Libre technology to as many people as possible," said Jared Watkin, senior vice president of Abbott's diabetes care business. "The French national reimbursement ...